1. Scrip
  2. >>Business

Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira

 
• By Brenda Sandburg

Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.

Coherus BioSciences Inc. is betting big on biosimilars, and is one of an elite group of pure play biosimilar specialists looking to compete against significantly bigger players. Though Coherus is a relatively little-known newcomer, it is one of just seven drug companies to have submitted a biosimilar application to FDA, along with marquee names like Sandoz Inc., Amgen Inc. and Pfizer Inc. – and it has the chance to be first to market in some lucrative categories.

The Redwood City, Calif.-based upstart could be the first to launch a biosimilar version of Amgen's blockbuster Neulasta (pegfilgrastim). Coherus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.

More from Scrip

In partnership with

Podcast Series: Navigating Regulatory & Market Shifts — CRO Perspectives on Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.